Sanofi Selects Recursion Treatment for Inflammatory Diseases
Sanofi selected an experimental treatment developed through its multi-program research collaboration with Recursion Pharmaceuticals. Recursion shares rose more than 16% on Thursday; the update also coincided with a $200 million stock offering.